Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223661 | 1.00 | ATM (0.39) | ATMHSD11B1 | |
| SCHEMBL10223663 | 1.00 | ATM (0.39) | ATMHSD11B1 | |
| SCHEMBL24777623 | 0.87 | ATM (0.37) | ATMHSD11B1 | |
| SCHEMBL10205027 | 0.87 | ATM (0.37) | ATMHSD11B1 | |
| SCHEMBL680053 | 0.86 | HSD11B1 (0.35) | ATMHSD11B1 | |
| SCHEMBL26080860 | 0.85 | ATM (0.36) | ATMHSD11B1 | |
| SCHEMBL24854369 | 0.83 | HRH3 (0.31) | — | |
| SCHEMBL24854017 | 0.83 | HRH3 (0.31) | — | |
| SCHEMBL24854068 | 0.83 | HRH3 (0.31) | — | |
| SCHEMBL24854370 | 0.83 | HRH3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | FMC CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20150218092-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2015-08-06 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278972-A1 | SUBSTITUTED HALOALKYL SULFONANILIDE HERBICIDES | CBR3, CBR1, GRHPR | ATM 4081/4885HSD11B1 846/4885 |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ATM 3321/4885HSD11B1 2454/4885 |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | ATM 332/4885HSD11B1 1944/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ATM 599/4885HSD11B1 4276/4885 |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | ATM 1962/4885HSD11B1 2583/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ATM 2274/4885HSD11B1 875/4885 |
| US-20150218092-A1 | PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | ATM 4506/4885HSD11B1 219/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | ATM 1067/4885HSD11B1 2803/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | ATM 1520/4885HSD11B1 4479/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | ATM 2133/4885HSD11B1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.